This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Acceleron Announces New Interim Phase 2 Sotatercept Clinical Data In Beta-Thalassemia To Be Presented At 2013 American Society Of Hematology Annual Meeting

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that data in five abstracts for sotatercept and ACE-536, Acceleron’s programs to treat red blood cell disorders, will be presented at the 55 th American Society of Hematology (ASH) Annual Meeting and Exposition. The conference will take place on December 7-10 th at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

Key information to be presented include new interim data from the ongoing phase 2 clinical trial of sotatercept in patients with beta-thalassemia. Initial interim data from the 0.5 mg/kg dose level will be presented in a poster presentation by the first author Maria-Domenica Cappellini, M.D., University of Milan, Milan, Italy on Monday December 9 th from 6:00 – 8:00 PM CST in Hall E of the convention center. Acceleron has previously provided interim clinical data from the 0.1 mg/kg and 0.3 mg/kg dose levels in this trial.

Additionally, preclinical data from both the sotatercept and ACE-536 programs will be presented at the meeting. Both sotatercept and ACE-536 are being jointly developed through a global collaboration with Celgene Corporation. The presentations from Acceleron, Celgene and academic collaborators will take place as follows:

Sotatercept Clinical Data

Abstract title: “A Phase 2a, Open-Label, Dose-Finding Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults with Beta (β)-Thalassemia: Interim Results”Abstract number: 3448Session: 112. Thalassemia and Globin Gene Regulation: Poster IIIDate: Monday, December 9, 2013Time: 6:00 PM – 8:00 PM CST (Ernest N. Morial Convention Center, Hall E)

Sotatercept Preclinical Data

Abstract title: “Sotatercept Promotes Differentiation and Survival of Erythroid Progenitors by Blocking Inhibitory Effects of TGFβ Superfamily Members”Abstract number: 944Session: 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism and Survival, Excluding Iron: Poster IDate: Saturday, December 7, 2013Time: 5:30 PM – 7:30 PM CST (Ernest N. Morial Convention Center, Hall E)

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,096.90 -106.47 -0.58%
S&P 500 2,098.62 -9.16 -0.43%
NASDAQ 4,967.1410 -12.76 -0.26%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs